Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety Evaluation of Use Sodic Enoxaparin (Enoxaparin)

This study has been completed.
Information provided by:
Azidus Brasil Identifier:
First received: May 5, 2008
Last updated: May 6, 2008
Last verified: January 2008
The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory Sanofi-Aventis in 60 patients with Chronic Renal Desease.

Condition Intervention Phase
Kidney Disease
Biological: Enoxaparin sodic
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Safety Evaluation of Use Sodic Enoxaparin Produced by the Laboratory Blausiegel When Compared With Product Clexane of Sanofi-Aventis Ltda in Chronic Renal Desease Patients.

Resource links provided by NLM:

Further study details as provided by Azidus Brasil:

Enrollment: 60
Study Start Date: January 2008
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Biological: Enoxaparin sodic

Detailed Description:

Hemodialysis is a filtering and cleaning process of endogenous and exogenous metabolic blood products. The level control of anticoagulants in patients with chronic renal disease is indispensable. Evidence of clotting as TTPa and evidence of activity of anti-factor Xa should be used as a substrate to protect these patients, undergoing dialysis. The Enoxaparin sodium is one that acts as antithrombin-factor Xa inhibitor of acting directly on the inactivation of antithrombin. Thus, small-chain molecules (low molecular weight) as Enoxaparin show fundamentally anti-Xa high end and low end antitrombotic. The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory Sanofi-Aventis in 60 patients with Chronic Renal Desease. The study was kind of parallel, randomized, double-blind and systematic sampling. The drugs were administered during 12 consecutive dialysis sessions at a dose of 1 mg / kg. The activity of the drugs was verified by the strength of markers TTPa and anti-Xa and security was seen through adverse reactions and the evaluation function of capillaries.

The study was conducted 60 patients with chronic renal desease to both sexes, above 18 years aged, who were carrying out haemodialysis treatment during 3 times a week and satisfied inclusion criteria. The investigational products were randomly administered to patients in 12 consecutive dialysis sessions, at a dose of 1 mg / kg. The primary endpoint was safety of using the drug evaluated by monitoring events as:

  • Loss of blood clotting by the system
  • Blood coagulation and loss of capillary vein.
  • Thrombus of capillary in 3 sessions of monitoring.
  • Increase in the patient's hematocrit
  • Thrombocytopenia
  • Hematoma
  • Fever
  • Allergic reactions

The secondary endpoint was evaluation of non inferiority clinic, observed over the criteria in maintaining the non-coagulation of the extracorporeal circuit during hemodialysis and the pharmacodynamic curve effect of enoxaparin sodium verified by the strength of markers TTPa, anti-Xa and anti-IIa.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults of both sexes, regardless of colour or social class;
  • Above 18 years age, with good clinical features, to medical criterion;
  • Patients who agreed to participate and signed the Informed Consent;
  • Patients with Chronic Kidney Disease in hemodialysis treatment (3 times per week);
  • Patients with clearance of creatinine <30ml/min;
  • Patients with details of anticoagulants during hemodialysis.

Exclusion Criteria:

  • Not agree to the terms described in Informed Consent;
  • Volunteers bearers of the sensitivity enoxaparin sodium;
  • Volunteers Patients with hypersensitivity to benzyl alcohol;
  • Volunteers with a history of bleeding or disease that change of blood clotting could aggravate or terminate the clinical picture, such as tables of gastric ulcer;
  • Volunteers with a history of peptic ulcer;
  • Patients with body mass index greater than 30;
  • Patients with cancer because of the possibility of compromising the function of the variable clotting;
  • Patients in a period of post-pregnancy or childbirth;
  • Patients with genetic abnormality of the system of coagulation;
  • Polytraumatized patients;
  • Patients in use of glucocorticoids for at least 1 month;
  • Patients in use of other anticoagulants;
  • Patients with high rate of bleeding;
  • Patients undergo any surgery performed less than 15 days due to the risk of the formation of bruising at the site of surgery.
  • Hypertension above 140/90 mmHg
  • Patients in use of medicines could affect the hemostasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00673426

Clinica TOP Nefrologia e Diálise
Americana, Brazil
Sponsors and Collaborators
Azidus Brasil
  More Information Identifier: NCT00673426     History of Changes
Other Study ID Numbers: ENOBLA0108
Study First Received: May 5, 2008
Last Updated: May 6, 2008

Keywords provided by Azidus Brasil:
chronic renal disease
Anticoagulant activity of enoxaparin sodic

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases processed this record on April 26, 2017